SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
Abstract
Sodium glucose cotransporter 2 inhibitors are a relatively new adjunctive treatment option for type 2 diabetes (T2D). Extraglycemic benefits of sodium glucose cotransporter 2 inhibition include weight and blood pressure reduction. Cherney et al. now demonstrate that these extraglycemic properties of empagliflozin are preserved despite reduced urinary glucose excretion in advancing chronic kidney disease. Limited therapeutic options for patients with type 2 diabetes in the latter stages of chronic kidney disease make empagliflozin an attractive therapeutic agent with additional cardiovascular benefits.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.